stockrowMirum Pharmaceuticals, Inc.
MIRM Healthcare Biotechnology
Mirum Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $521.3 million, up 54.7% from fiscal 2024.
- Revenue
- +39.6%
- EPS
- −1,136.8%
- Free cash flow
- −114.2%
- Total debt
- +136.4%
Quarter to September 2026, against a year earlier
Follow MIRM
Alert me
Mirum Pharmaceuticals, Inc. (MIRM) Shares outstanding
Mirum Pharmaceuticals, Inc.'s shares outstanding at the end of fiscal 2025 was $50.2M, up 5.63% from $47.5M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $66.1M. Over the past ten years it has ranged from $899.0K (fiscal 2018) to $50.2M (fiscal 2025) — the current reading is the highest in ten years. Mirum Pharmaceuticals, Inc. ranks 229th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $50.2M | 5.63% |
| FY2024 | $47.5M | 16.24% |
| FY2023 | $40.9M | 20.31% |
| FY2022 | $34.0M | 12.07% |
| FY2021 | $30.3M | 20.08% |
| FY2020 | $25.3M | 119.85% |
| FY2019 | $11.5M | 1,177.64% |
| FY2018 | $899.0K | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $66.1M | 4.22% |
| Jun 2026 | $63.4M | 7.69% |
| Mar 2026 | $58.9M | 17.24% |
| Dec 2025 | $50.2M | (11.92%) |
| 28 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| IMVT Immunovant, Inc. compare | $205.5M |
| IONS Ionis Pharmaceuticals, Inc. compare | $165.4M |
| CGON CG Oncology, Inc. compare | $88.2M |
| PTCT PTC Therapeutics, Inc. compare | $83.5M |
| MIRM Mirum Pharmaceuticals, Inc. | $66.1M |
| ORKA Oruka Therapeutics, Inc. compare | $62.9M |
| KOD Kodiak Sciences Inc. compare | $62.6M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | $40.2M |
| LGND Ligand Pharmaceuticals Incorporated compare | $20.0M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on MIRM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement